Figure 3 - uploaded by Miroslav Brtko
Content may be subject to copyright.
Effect of rosiglitazone vs glipizide on the primary outcome of change in PAV according to predefined subgroups in patients with 2 evaluable IVUS measures. P values reflect the test for an interaction between the subgroups and allocation to rosiglitazone vs glipizide. Median values are as follows: body mass index (BMI), 28.9 kg/m 2 ; diabetes mellitus duration, 4.9 years; hemoglobin A 1C , 7.1%; HDL, 42.5 mg/dL; LDL, 87.0 mg/dL; triglycerides, 165.0 mg/dL; high-sensitivity C-reactive protein (hsCRP), 5.2 mg/L; PAV, 41.3%. AS indicates Asia; EU, Europe, NA, North America, SA, South America; OAD, oral antidiabetic drug; SU, sulfonylurea; and BP, blood pressure. 

Effect of rosiglitazone vs glipizide on the primary outcome of change in PAV according to predefined subgroups in patients with 2 evaluable IVUS measures. P values reflect the test for an interaction between the subgroups and allocation to rosiglitazone vs glipizide. Median values are as follows: body mass index (BMI), 28.9 kg/m 2 ; diabetes mellitus duration, 4.9 years; hemoglobin A 1C , 7.1%; HDL, 42.5 mg/dL; LDL, 87.0 mg/dL; triglycerides, 165.0 mg/dL; high-sensitivity C-reactive protein (hsCRP), 5.2 mg/L; PAV, 41.3%. AS indicates Asia; EU, Europe, NA, North America, SA, South America; OAD, oral antidiabetic drug; SU, sulfonylurea; and BP, blood pressure. 

Similar publications

Article
Full-text available
Over the last two decades coronary artery calcium (CAC) scanning has emerged as a quick, safe, and inexpensive method to detect the presence of coronary atherosclerosis. Data from multiple studies has shown that compared to individuals who do not have any coronary calcifications, those with severe calcifications (i.e., CAC score >300) have a 10-fol...

Citations

... The result also has been reported in SYMPHONY substudy [51]. Although these studies highlighted the central role of insulin resistance in progression of atherothrombotic events in DM patients, these outcomes have not been established in the later published APPROACH trial [52]. In this study, there was no significant difference between the group treated with thiazolinedione rosiglitazone and the group treated with glipizide, an insulin secretagogue, in patients with type-2 DM and CAD [52]. ...
... Although these studies highlighted the central role of insulin resistance in progression of atherothrombotic events in DM patients, these outcomes have not been established in the later published APPROACH trial [52]. In this study, there was no significant difference between the group treated with thiazolinedione rosiglitazone and the group treated with glipizide, an insulin secretagogue, in patients with type-2 DM and CAD [52]. ...
Article
Patients with Diabetes Mellitus (DM) have accelerated atherosclerosis, which is the main essential factor contributing to the high risk of atherothrombotic events in these patients. Atherothrombotic complications are the principal cause of morbidity and mortality in patients with DM. Both atherosclerosis and the increased risk of thrombotic vascular events may result from dyslipidaemia, endothelial dysfunction, platelet hyperreactivity, an impaired fibrinolytic balance, and abnormal blood flow. Platelets of DM patients are characterised by dysregulation of several signalling pathways causing increased adhesion, activation and aggregation. Platelet function of patients with DM is complicated by several mechanisms, such as hyperglycaemia, insulin deficiency and resistance, associated metabolic conditions, and cellular abnormalities. The present manuscript purposes to provide a review on the up-to-date status of data on platelet abnormalities that characterise patients with DM.
... Moreover, there is a lack of data to indicate that IVUS-gated image analysis enables more reproducible quantification of atheroma burden than conventional IVUS segmentation at 1 mm interval. [14][15][16] We have recently introduced a novel deep-learning (DL) methodology that is capable of retrospectively detecting the end-diastolic (ED) frames in an IVUS sequence within 15 s. The proposed methodology has been incorporated in a user-friendly IVUSanalysis software (QCU-CMS version 4.69; Leiden, University Medical Center, Leiden, The Netherlands), has been validated against ECGestimations and it has been found to have an excellent accuracy in correctly detecting the ED frames. ...
Article
Full-text available
Background Volumetric intravascular ultrasound (IVUS) analysis is currently performed at a fixed frame interval, neglecting the cyclic changes in vessel dimensions occurring during the cardiac cycle that can affect the reproducibility of the results. Analysis of end-diastolic (ED) IVUS frames has been proposed to overcome this limitation. However, at present, there is lack of data to support its superiority over conventional IVUS. Objectives The present study aims to compare the reproducibility of IVUS volumetric analysis performed at a fixed frame interval and at the ED frames, identified retrospectively using a novel deep-learning methodology. Methods IVUS data acquired from 97 vessels were included in the present study; each vessel was segmented at 1 mm interval (conventional approach) and at ED frame twice by an expert analyst. Reproducibility was tested for the following metrics; normalized lumen, vessel and total atheroma volume (TAV), and percent atheroma volume (PAV). Results The mean length of the analyzed segments was 50.0 ± 24.1 mm. ED analysis was more reproducible than the conventional analysis for the normalized lumen (mean difference: 0.76 ± 4.03 mm³ vs. 1.72 ± 11.37 mm³; p for the variance of differences ratio < 0.001), vessel (0.30 ± 1.79 mm³ vs. −0.47 ± 10.26 mm³; p < 0.001), TAV (−0.46 ± 4.03 mm³ vs. −2.19 ± 14.39 mm³; p < 0.001) and PAV (−0.12 ± 0.59% vs. −0.34 ± 1.34%; p < 0.001). Results were similar when the analysis focused on the 10 mm most diseased segment. The superiority of the ED approach was due to a more reproducible detection of the segment of interest and to the fact that it was not susceptible to the longitudinal motion of the IVUS probe and the cyclic changes in vessel dimensions during the cardiac cycle. Conclusions ED IVUS segmentation enables more reproducible volumetric analysis and quantification of TAV and PAV that are established end points in longitudinal studies assessing the efficacy of novel pharmacotherapies. Therefore, it should be preferred over conventional IVUS analysis as its higher reproducibility is expected to have an impact on the sample size calculation for the primary end point.
... In addition, in APPROACH, rosiglitazone did not obviously reduce the primary outcome of percentage of atherosclerotic volume (−0.64%; 95% CI 1.46-0.17; P = 0.12) compared to glipizide [71]. However, a prospective study reported a significantly lower incidence of instent restenosis at 6 months in the rosiglitazone group compared with the control group (stent lesion: 17.6 vs. 38.2%, ...
Article
Type 2 diabetes mellitus (T2DM) is a chronic disease prevalent in the world, and it is also one of the overall factors leading to overall morbidity and mortality. Throughout Asia, the proportion of people with T2DM and obesity has increased and this growth rate shows no signs of slowing down. Thiazolidinediones (TZDs) can specifically treat insulin resistance and improve metabolic syndrome, including rosiglitazone, troglitazone and pioglitazone, which are peroxisome proliferator-activated receptor (PPAR) agonists. These drugs have been shown to have better therapeutic effect and glycemic control, but also accompanied by a series of adverse reactions. Cardiovascular events are currently the most serious adverse events of rosiglitazone, which cardiovascular toxicity is higher than pioglitazone. Rosiglitazone has been restricted or even withdrawal from the market in most countries owing to concerns about its cardiovascular safety, while its beneficial effect on insulin resistance has been demonstrated. New data on rosiglitazone-mediated heart failure, myocardial infarction and fractures provide clinicians with prescriptions with fewer side effects to treat patients. Studies have shown that rosiglitazone is the most effective treatment in TZDs (in vivo study), not only hypoglycemic effect but with some additional effects, such as anti-inflammatory and anti-cancer capabilities, retinopathy (animal models) and ischemia–reperfusion injury protection effects, lipid regulation and blood pressure reduction, etc. Although rosiglitazone shows the highest risk of arrhythmia in diabetes management while has the capacity to reduce the risk of atrial fibrillation.
... In an 18-month study of 672 subjects with T2D and at least 1 atherosclerotic plaque with luminal narrowing in a coronary artery who were randomized to rosiglitazone or glipizide, there was no significant difference in percent atheroma volume (95% CI = − 1.46-0.17 p = 0.12) [59]. In a controlled, randomized study of 83 participants with diabetes who had percutaneous coronary artery stent placement, rosiglitazone significantly reduced restenosis at 6 months compared with the control treatment (17.6 vs. 38.2%, ...
Article
Full-text available
Purpose of Review Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular risk factors associated with insulin resistance have been well documented. TZD use has been limited because of concern about safety issues and side effects. Recent Findings Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone are no longer significant issues. There are new data which show that pioglitazone treatment reduces myocardial infarctions and ischemic strokes. New data concerning TZD-mediated edema, congestive heart failure, and bone fractures improves the clinician’s ability to select patients that will have minimal significant side effects. Summary Thiazolidinediones are now generic and less costly than pharmaceutical company–promoted therapies. Better understanding of the side effects coupled with clear benefits on the components of the insulin resistance syndrome should promote TZD use in treating patients with type 2 diabetes.
... The net effect of TZDs is an increased mass of small insulin-sensitive subcutaneous adipocytes with decreased lipolytic activity, resulting in decreased free fatty acids concentration and improved adipocytokine profile. 145 Similarly to SUF and insulin treatment, TZDs may lead to weight gain, partly due to TZDs' most common side effect, fluid retention, which might foster the formation of peripheral edema in patients with cardiac or renal disease. 146 Because of the potential for long-term adverse effect, TZDs use has been subject of debate with one molecule in this class, troglitazone (TRO) being taken off-market since the year 2000 due to increased incidence of drug-induced hepatitis, and rosiglitazone (ROSI) being suspected of bringing cardiovascular harm and retracted by the Food and Drug Administration at first, but later it has been restored in the US market. ...
Article
Full-text available
Type 2 diabetes mellitus (T2DM) is a chronic disease that has reached the levels of a global epidemic. In order to achieve optimal glucose control it is often necessary to rely on combination therapy of multiple drugs or insulin, because uncontrolled glucose levels result in T2DM progression and enhanced risk of complications and mortality. Several anti‐hyperglycemic agents have been developed over time, and T2DM pharmacotherapy should be prescribed based on suitability for the individual patient's characteristics. Pharmacogenetics is the branch of genetics that investigates how our genome influences individual responses to drugs, therapeutic outcomes, and incidence of adverse effects. In this review we evaluated the pharmacogenetic evidences currently available in the literature and we identified the top informative genetic variants associated with response to the most common anti‐diabetic drugs: metformin, DPP‐4 inhibitors/GLP1R agonists, thiazolidinediones and sulfonylureas/meglitinides. Overall we found 40 polymorphisms for each drug class in a total of 71 loci, and we examined the possibility of encouraging genetic screening of these variants/loci in order to critically implement decision making about the therapeutic approach through precision medicine strategies. It is possible then to anticipate that when the clinical practice will take advantage of the genetic information of the diabetic patients, this will provide a useful resource for the prevention of T2DM progression, enabling the identification of the precise drug that is most likely to be effective and safe for each patient, and the reduction of the economic impact on a global scale.
... Thus, diabetic medications may have additional benefit. A trial in type two diabetic patients with coronary artery disease ( n = 672) found no significant difference between rosiglitazone and glipizide treatment effect on atherosclerosis volume in vessels with non-obstructive coronary artery disease and no prior percutaneous intervention as assessed by IVUS at 18 months [93] . Neither therapy resulted in atherosclerosis regression although progression was not observed. ...
Article
Atherosclerotic coronary artery disease continues to be a major global health burden in developing and developed nations. Newer imaging techniques afford an accurate assessment of plaque burden and characteristics as well as the effects of treatment. Lifestyle interventions and pharmacotherapy remain the mainstay of non-interventional treatment of coronary atherosclerosis, with reversal seen in many studies. In addition, control of modifiable risk factors can be beneficial. As a better understanding of atherosclerosis pathophysiology is achieved, new therapeutic targets and combination therapies may join the armamentarium that promotes regression of atherosclerotic plaque. We present a review of the literature regarding lifestyle and medical therapies that can promote the reversal of coronary atherosclerosis.
... It is widely known that type 2 diabetes is considered a 'risk equivalent' for cardiovascular disease. Rosiglitazone, a thiazolidinedione, has been investigated as a potential therapeutic agent for the prevention of cardiovascular disease, such as atherosclerosis (2)(3)(4). ...
Article
Full-text available
Abnormal collagen deposition, as well as collagen metabolism, plays a crucial role in the formation and progression of vulnerable atherosclerotic plaques (VAPs), which are susceptible to rupture. According to our previous findings, rosiglitazone, a thiazolidinedione, can promote the stability of atherosclerotic plaques in fat-fed ApoE-knockout mice; however, it is unknown whether it can modulate collagen deposition and metabolism in VAPs. The present study was designed to determine the effect of rosiglitazone on collagen deposition and metabolism in the plaques of fat-fed ApoE-knockout mice. Following 13 weeks of the high-fat diet, the mice were randomized into three groups (10 mice/group) and intragastrically administered rosiglitazone, simvastatin and distilled water, respectively, for a further 13 weeks. The category of the collagen present in the plaques was evaluated using the picro-Sirius red polarization method. Additionally, the protein expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the plaques was determined using immunohistochemistry. The results showed that rosiglitazone reduced the lipid to collagen and type III to type I collagen ratios in the plaques, and these reductions were correlated with the reduction in the plaque MMP-9 to TIMP-1 ratio. These results suggest that rosiglitazone can modulate collagen deposition and metabolism and promote the stabilization of VAPs.
... Peroxisome proliferator-activated receptor (PPAR)γ agonists, such as rosiglitazone, are extensively used in the treatment of type 2 diabetes (13). These agonists have also been shown to exert anti-atherogenic effects in subjects with or without diabetes (14)(15)(16)(17). PPARγ is primarily found in adipose tissue and arterial wall cells, such as endothelial cells, vascular smooth muscle cells and monocytes/macrophages where it modulates lipid metabolism (18). ...
Article
Full-text available
Rosiglitazone has been found to have anti-atherogenic effects and to increase serum high-density lipoprotein (HDL) cholesterol (HDL-C) levels. However, in vivo studies investigating the regulation of adenosine triphosphate-binding cassette transporter A1 (ABCA1) and scavenger receptor class B type I (SR-BI) by rosiglitazone are limited. Moreover, the effects of rosiglitazone on the function and levels of HDL are unclear. In the present study, we investigated the effects of rosiglitazone on HDL function and its mechanisms of action in atherosclerotic rabbits. Our results revealed that rosiglitazone induced a significant increase in serum HDL-C levels, paraoxonase 1 (PON1) activity, [3H]cholesterol efflux rates, and the expression of ABCA1 and SR-BI in hepatocytes and peritoneal macrophages. The expression of ABCA1 was also increased in aortic lesions. Rosiglitazone markedly reduced serum myeloperoxidase (MPO) activity, aortic intima-media thickness (IMT) and the percentage of plaque area in the aorta. It can thus be concluded that in atherosclerotic rabbits, rosigitazone increases the levels of HDL-C and hinders atherosclerosis. Thus, it improves HDL quality and function, as well as the HDL-induced cholesterol efflux, exerting anti-inflammatory and antioxidant effects.
... Two studies have addressed this question. The APPROACH (The Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in Diabetes Patients With Cardiovascular History; rosiglitazone study) 64 and the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation; pioglitazone study) trials. 65 The change in PAV in the APPROACH study was not different in patients allocated to glipizide or rosiglitazone (−0.64%; 95% CI, −1.46 to 0.17; P=0.12), whereas in the PERISCOPE study pioglitazone versus glimepiride was associated with favorable effects on change of PAV (−0.16±0.21 ...
Article
Culprit lesions of patients, who have had an acute coronary syndrome commonly, are ruptured coronary plaques with superimposed thrombus. The precursor of such lesions is an inflamed thin-capped fibroatheroma. These plaques can be imaged by means of invasive techniques, such as intravascular ultrasound (and derived techniques), optical coherence tomography, and near-infrared spectroscopy. Often these patients exhibit similar (multiple) plaques beyond the culprit lesion. These remote plaques can be assessed noninvasively by computed tomographic angiography and MRI and also using invasive imaging. The detection of these remote plaques is not only feasible but also in natural history studies have been associated with clinical coronary events. Different systemic pharmacological treatments have been studied (mostly statins) with modest success and, therefore, newer approaches are being tested. Local treatment for such lesions is in its infancy and larger, prospective, and randomized trials are needed. This review will describe the pathological and imaging findings in culprit lesions of patients with acute coronary syndrome and the assessment of remote plaques. In addition, the pharmacological and local treatment options will be reviewed.
... The results are also consistent with the significant slowing of coronary atherosclerosis [measured using intravascular ultrasound (IVUS)] and carotid intima-media thickness (CIMT) progression that has been reported for pioglitazone vs. glimepiride in two large-scale prospective imaging trials [30,31]. Interestingly, a recent coronary IVUS study suggested a similar benefit for rosiglitazone compared with glipizide, but the primary outcome had a broad CI for rosiglitazone (indicating a high variability in response) and it failed to reach statistical significance [32]. ...
Article
Full-text available
Given the continued interest in defining the optimal management of individuals with type 2 diabetes, the Editor of Diabetes Care convened a working party of diabetes specialists to examine this topic in the context of insulin therapy. This was prompted by recent new evidence on the use of insulin in such people. The group was aware of evidence that the benefits of insulin therapy are still usually offered late, and thus the aim of the discussion was how to define the optimal timing and basis for decisions regarding insulin and to apply these concepts in practice. It was noted that recent evidence had built upon that of the previous decades, together confirming the benefits and safety of insulin therapy, albeit with concerns about the potential for hypoglycemia and gain in body weight. Insulin offers a unique ability to control hyperglycemia, being used from the time of diagnosis in some circumstances, when metabolic control is disturbed by medical illness, procedures, or therapy, as well as in the longer term in ambulatory care. For those previously starting insulin, various other forms of therapy can be added later, which offer complementary effects appropriate to individual needs. Here we review current evidence and circumstances in which insulin can be used, consider individualized choices of alternatives and combination regimens, and offer some guidance on personalized targets and tactics for glycemic control in type 2 diabetes.